Hemogenyx Pharmaceuticals Plc (HOPHF)
OTCMKTS
· Delayed Price · Currency is USD
1.240
+1.200 (3,000.00%)
Mar 7, 2025, 4:00 PM EDT
Hemogenyx Pharmaceuticals Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
9.88M USD
Revenue Chart
* This company reports financials in GBP.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Hemogenyx Pharmaceuticals News
- 4 days ago - Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director's Dealing - Accesswire
- 10 days ago - Hemogenyx Pharmaceuticals PLC Announces Second Patient Treated with HG-CT-1 CAR-T Therapy - Accesswire
- 14 days ago - Hemogenyx Pharmaceuticals reports FY results - Seeking Alpha
- 5 weeks ago - Hemogenyx Pharmaceuticals PLC Announces FDA Annual Report - Accesswire
- 7 weeks ago - Hemogenyx Pharmaceuticals PLC Announces First Patient Safety - Accesswire
- 2 months ago - Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials - Accesswire
- 2 months ago - Hemogenyx Pharmaceuticals PLC Announces Institutional Investment - Accesswire
- 2 months ago - Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1 - Accesswire